A positive clinical trial is usually a signal for a biotech startup to press the accelerator on its spending, but Kronos Bio is taking a different tack.
The Californian biotech is axing 19% of its workforce and putting some very early-stage R&D programmes on hold in order to plough its resources into lead drug KB-0742, which has just generated positive safety and efficacy data in a phase 1/2 study in solid tumours and non-Hodgkin lymphoma (NHL).
